1681 — Consun Pharmaceutical Income Statement
0.000.00%
Last trade - 00:00- HK$14.36bn
- HK$10.51bn
- CNY3.42bn
Annual income statement for Consun Pharmaceutical, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | HKAS | HKAS | HKAS | HKAS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 2,045 | 2,340 | 2,590 | 2,967 | 3,417 |
| Cost of Revenue | |||||
| Gross Profit | 1,527 | 1,763 | 1,922 | 2,242 | 2,667 |
| Selling / General / Administrative Expenses | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1,336 | 1,582 | 1,705 | 1,922 | 2,215 |
| Operating Profit | 709 | 757 | 885 | 1,045 | 1,202 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | 696 | 746 | 864 | 1,020 | 1,196 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 587 | 684 | 787 | 917 | 1,089 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 590 | 683 | 785 | 910 | 1,078 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 590 | 683 | 785 | 910 | 1,078 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.735 | 0.864 | 0.983 | 1.09 | 1.26 |
| Dividends per Share | |||||
| Special Dividends per Share |